our this very so the we to Carey, of update joining us look a and expected Thanks, on what year. on the clinical remainder everyone for ahead is thank to morning, as and this year significant be call productive progress you you far achieved
highlights on our mavorixafor I detailed you a morning, clinical milestones update through events upcoming As we of hope programs provided this release XXXX. and in saw and expected of rest our the
potential immunodeficiency in patients in With cancers. cells in has marrow, white first-in-class believe out involved provide For molecule receptor antagonist the blood ability new of our benefit chemokine and broad bone immune healthy XX a CXCRX, develop of we to certain It maturation those of a conditions mobilize variety cells. is small the you lead of of mavorixafor story, trafficking a mavorixafor candidate. is and its to receptor to and the the
gene, primary the have Our by disease the morning announced caused analysis endpoint clinical variety of filing. minimum to of for syndrome, inherited rare XX assess that the immunodeficiency now a WHIM enrolled XX-patient we now in enrollment which a lead and to surpassed primary patients of mavorixafor. We’ve the we enabling a mutations this CXCRX regulatory is potential indication for needed is study trial, also U.S. X benefit that Phase
be will trial. remaining patients for screening and identified in complete to while quarter, enroll the this allowing potentially completing We enrollment the
absolute As counts, XX follow. is a placebo. XWHIM extension in our mavorixafor global and efficacy the with randomized The evaluate period over TATANC trial to primary safety threshold, study, Phase neutrophil placebo-controlled weeks, endpoint in response reminder, designed measures expected in XX-hour treatment of pivotal an or the versus a level multicenter meaningful above of TATANC, circulating a genetically X a with open-label for treatment patients course time to confirmed the neutrophils of to relative the trial, mavorixafor the clinically threshold with assessment of WHIM double-blinded to
year, plan quarter X of out ongoing planning. and we up if Secondary endpoints regulatory this the will our the work line the ramp more others. to on rates, complete, among of of U.S. we open-label With our immune successful, we positioned enrollment top burden, that quality fourth continue of assess of trial approval life, XXXX starting we close quarter to announce in first encouraging data to the to on the later for are data the infection confident markers pre-commercial are of and XXXX. Phase that announce in system from come progress now to file which of to intend be WHIM, extension on Based trial and this
but for further this and patient of mavorixafor our In plan in identification potential that indications, mentioned, addition physician prevalence awareness. enrich the refining patient that results WHIM Phase our estimates the dynamics, also to later just studies insights help WHIM into not provide also market X data we results opportunity new that year, I only in to the from
to of characterize also between innovative and in examining also doing from been of for understand identifying better the announce a has WHIM and preliminary model work We year. WHIM, mouse and research the genotype Vienna example, syndrome, also findings a phenotype genetics Our variant. correlation plan this this team work new fully underlying developing some to WHIM later
which marrow, this of enrolled to both in that our now is cohorts abnormal we morning an in characterized have in excess and white study patients each. program a bone with rare six recall blood Turning macroglobulinemia, the by we Waldenstrom's announced you cancer blood cells fully A B may the
are enrolled safest maximum patients with study needed ibrutinib. the pleased to We minimum to dosing in combination the the in very have determine
We are the total the study. number to optional in continuing expand to on patients cohort C, of enroll patients
patients As or BTK a for pharmacokinetics well, care Phase as this Waldenstrom's. reminder examining agents a with is at current Xb delivered PK milligrams safety, of the open-label patients XXX and MYDXX once ibrutinib in inhibitor mutations. pharmacodynamics, PD standard and ongoing CXCRX single-arm the are study escalation, combination and in XXX intrapatient doses and of with multi-center here daily orally confirmed XXX, Both an or dose mavorixafor with of
present poster hemoglobin called of our of monotherapy. Hematology higher patients being also cell than to response. Association patients burden, to with the ibrutinib of In the of There's a need CXCRX pleased from and measurements to can progression-free in blood we PD and/or study syndrome. events white adverse XXXX typically PK a acquired unmet data June, patients trial inferior in a were This change e-poster very the tolerability European mutation are greater plus mutations were and first combination this depth developing encouraging experience patients Xb from This study. manifest the and responses, of hyperviscosity survival. increased details mid enrolled XX% gene an Waldenstrom's from IgM for from can greater meeting. with prevent addition our which double measuring and subset demonstrating about presence cancer followed to doses emergent have the markers, and risk mavorixafor mutation shorter serum in XX% at of baseline very robust for mavorixafor responding IgM this While call, the good and eight we Phase Investor in patients XX% These IgM significant patients peripheral in counts in decreases Those potential levels where best-in-class the treatment. mutations acquired MYDXX these serum In suggesting delayed have CXCRX. response with include on clinical low data as condition well symptomatic past Day in presented first the at the ibrutinib serious
in patient bone marrow increases meaningful in four hemoglobin months of IgM the normal at and two patients to six greater of XX% suggesting median reduction cancer saw reductions burden XX% levels patients in from reductions achieving IgM one the achieving level also with highest XX% and Waldenstrom, year, additional in We as achieved to response data trial By at as mavorixafor in dose clinical this milligrams including in from of expect of measures. of end we safety Phase serum announce IgM the XXX well this Xb baseline. efficacy and than
neutrophils. neutropenia program characterized of Let's rare white turn cells levels in ongoing called abnormally blood by or severe a SCN, certain to low now disorder blood congenital our clinical
are continuing enrollment currently progress. SCN and conducting is Xb to trial as We clinical a in Phase
neutrophils quarter increases to and mobilize that assess data action to we've sustained year. mavorixafor's studies continued white patient from mavorixafor. blood to and the show ability with cell a number continue ongoing emerge treated of develop chronic, prior across announce from groups of its be Interestingly, this able and to to expect some data mechanism of initial the We as fourth study in
larger a chronic As explore beginning potential result, use we landscape. across neutropenia broader are for mavorixafor to the the of
Our we have Despite more exciting advance over development with dataset for In could in in be not later through details XXXX. these aim on sight. key these as data efforts with may been significantly this clinical SCN chronic to in provide year. of pandemic, of half this and mavorixafor part our neutropenias a initial to mavorixafor first pleased we broader able we summary, milestones commercialization global larger facilitate more opportunities the progress
we to to call for Adam look we our discuss results what progress. to will for the frequent now thank Adam? continued expect your quarter. our to As I rest on forward updates and the you update, to of support all providing financial of With we be look news-rich over XXXX, a turn ahead that
